Sumitomo Mitsui DS Asset Management Company Ltd Purchases 657 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,863 shares of the company’s stock after buying an additional 657 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Moderna were worth $1,450,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Blue Trust Inc. raised its position in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares in the last quarter. Larson Financial Group LLC grew its stake in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. Rakuten Securities Inc. increased its holdings in Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the period. Finally, Brooklyn Investment Group bought a new position in shares of Moderna during the 3rd quarter worth approximately $80,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Berenberg Bank upped their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research report on Monday, November 18th. Sanford C. Bernstein initiated coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Finally, Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $66.89.

Moderna Stock Down 2.9 %

MRNA stock opened at $30.93 on Wednesday. The stock has a market cap of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $39.77 and its two-hundred day simple moving average is $56.76. Moderna, Inc. has a 1-year low of $30.70 and a 1-year high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.